137 related articles for article (PubMed ID: 27896440)
1. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Sehouli J; Tomè O; Dimitrova D; Camara O; Runnebaum IB; Tessen HW; Rautenberg B; Chekerov R; Muallem MZ; Lux MP; Trarbach T; Gitsch G
J Cancer Res Clin Oncol; 2017 Mar; 143(3):541-550. PubMed ID: 27896440
[TBL] [Abstract][Full Text] [Related]
2. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
3. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
[TBL] [Abstract][Full Text] [Related]
4. A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.
Mahner S; Oskay-Özcelik G; Heidrich-Lorsbach E; Fuxius S; Sommer H; Klare P; Belau A; Ruhmland B; Heuser T; Kölbl H; Markmann S; Sehouli J
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1413-9. PubMed ID: 22526159
[TBL] [Abstract][Full Text] [Related]
5. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
Meden H; Wittkop Y; Kuhn W
Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
[TBL] [Abstract][Full Text] [Related]
6. Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer.
Hilger RA; Jacek G; Oberhoff C; Kredtke S; Baumgart J; Seeber S; Scheulen ME
Cancer Chemother Pharmacol; 2000; 45(6):483-8. PubMed ID: 10854136
[TBL] [Abstract][Full Text] [Related]
7. Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.
Chekerov R; Harter P; Fuxius S; Hanker LC; Woelber L; Müller L; Klare P; Abenhardt W; Nedkova Y; Yalcinkaya I; Heinrich G; Sommer H; Mahner S; Wimberger P; Koensgen-Mustea D; Richter R; Oskay-Oezcelik G; Sehouli J;
Gynecol Oncol Res Pract; 2017; 4():6. PubMed ID: 28286660
[TBL] [Abstract][Full Text] [Related]
8. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
9. Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients.
Grabowski JP; Richter R; Rittmeister H; Chekerov R; Woopen H; Sehouli J
Anticancer Res; 2018 Oct; 38(10):5853-5858. PubMed ID: 30275210
[TBL] [Abstract][Full Text] [Related]
10. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma.
Masding J; Sarkar TK; White WF; Barley VL; Chawla SL; Boesen E; Rostom AY; Menday AP
Br J Obstet Gynaecol; 1990 Apr; 97(4):342-51. PubMed ID: 2187525
[TBL] [Abstract][Full Text] [Related]
11. The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Woopen H; Richter R; Chekerov R; Siepmann T; Ismaeel F; Sehouli J
Gynecol Oncol; 2015 Sep; 138(3):735-40. PubMed ID: 26185017
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Karlan BY; Oza AM; Richardson GE; Provencher DM; Hansen VL; Buck M; Chambers SK; Ghatage P; Pippitt CH; Brown JV; Covens A; Nagarkar RV; Davy M; Leath CA; Nguyen H; Stepan DE; Weinreich DM; Tassoudji M; Sun YN; Vergote IB
J Clin Oncol; 2012 Feb; 30(4):362-71. PubMed ID: 22184370
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
[TBL] [Abstract][Full Text] [Related]
15. Treosulfan as an effective second-line therapy in ovarian cancer.
Gropp M; Meier W; Hepp H
Gynecol Oncol; 1998 Oct; 71(1):94-8. PubMed ID: 9784326
[TBL] [Abstract][Full Text] [Related]
16. A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG).
Reed NS; Poole CJ; Coleman R; Parkin D; Graham JD; Kaye SB; Ostrowski J; Duncan I; Paul J; Hay A;
Eur J Cancer; 2006 Jan; 42(2):179-85. PubMed ID: 16337372
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.
Woopen H; Richter R; Inci G; Alavi S; Chekerov R; Sehouli J
Support Care Cancer; 2020 Apr; 28(4):1997-2003. PubMed ID: 31385100
[TBL] [Abstract][Full Text] [Related]
18. Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
Bojko P; Hilger RA; Ruehm SG; Dirsch O; Seeber S; Scheulen ME
Bone Marrow Transplant; 2003 Mar; 31(6):487-91. PubMed ID: 12665845
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan in the treatment of advanced ovarian cancer: a randomised co-operative multicentre phase III-study.
Breitbach GP; Meden H; Schmid H; Kühn W; Sass G; Schach S; Schmidt-Rohde P; Bastert G;
Anticancer Res; 2002; 22(5):2923-32. PubMed ID: 12530019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]